Molecular Tumor Board at the Center for Personalized Medicine Tübingen
- Conditions
- Advanced Cancer
- Registration Number
- NCT03503149
- Lead Sponsor
- University Hospital Tuebingen
- Brief Summary
Molecular Tumor Board at the Center for Personalized Medicine
- Detailed Description
Molecular Tumor Board at the Center for Personalized Medicine The study objectives are
* To ensure a prospective documentation of all patients who are referred to the Molecular Tumor Board in routine clinical care
* To prospectively ensure the documentation of MTB patients with an emphasis to clinical outcome parameters progression-free survival (PFS), overall survival (OS) and further response assessments (e.g. peripheral immunmonitoring, imaging parameters)
* To prospectively assess patient-reported outcome of MTB patients
* To evaluate compliance to MTB suggestions in routine clinical care
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1000
- Given informed consent ("broad consent" of the University Hospital Tübingen)
- ≥ 18 years of age
- Clinical indication for a referral to Molecular Tumor Board by the treating physician
- The MTB assists the referring physician with the interpretation and the use of tumor molecular profiling data for deciding on a therapeutic strategy. Therefore, this board is confined to cancer patients and cannot provide any service for non-cancer patients
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival 6 months Progression-free survival
- Secondary Outcome Measures
Name Time Method Overall survival an average of 1 year Progression-free survival
Trial Locations
- Locations (1)
University Hospital Tübingen
🇩🇪Tübingen, BW, Germany